In this tutorial, you will learn how to group standalone sequences into a sequence list and pair heavy and light chains prior to sequence annotation.
This tutorial will cover the following exercises:
- Group sequences
- Chain association
- Sequence annotation
- Assay data
- Filtering on assay data
- Sequence alignment
Get started: To start this tutorial, you will need the input data. If you have recently started Geneious Biologics, your organisation may already have the tutorial folders set up as described in the tutorial below. If not, you can still follow this tutorial by first downloading the input sequences here and then uploading them into Geneious Biologics.
Sequence lists make it easier to manage large numbers of sequences by grouping related sequences into a single document.
In this exercise, you will learn how to group multiple nucleotide sequences into a Nucleotide Sequence List. To group the standalone clinical-stage antibody sequences into a sequence list, select all the sequences located in the Input data folder, click Pre-processing Group Sequences.
In the example above, the 274 standalone sequences in the Input data folder were grouped into a single Nucleotide Sequence List named Clinical-stage antibodies..
**Note that you can also group multiple Sequence Lists into a single Sequence List.
Heavy and light chain pairing
Previous studies have shown that the interaction between the heavy and light chain variable regions may alter the positions of hypervariable loops and in turn affect the confirmation of the antigen binding site. The Pair Heavy/Light Chains operation pairs heavy and light sequences allowing these sequences to be analysed as a single molecule.
In this exercise, you will learn how to pair heavy and light chain sequences with similar names. To associate corresponding heavy and light chain sequences by naming conventions, first, select the Clinical-stage antibodies Sequence List, click Pre-processing Pair Heavy/Light Chains. Then, select the Match sequence names (for standalone sequences, or within each list) (slow) in the Pair Heavy/Light dialog box option to pair sequences with similar name.
This operation will produce a Clinical-stage antibodies (paired) document. To view the paired sequences, select the Clinical-stage antibodies (paired) document in the Chain association folder.
In the example above, the sequences are paired by named (indicated by the paired-reads icon and the red outlined encompassing the paired reads). Learn more about heavy and chain pairing here.
The Antibody Annotator is a versatile pipeline that identifies and annotates both NGS-type and Sanger-type sequences in reference to an immunoglobulin reference database.
In this exercise, you will learn how to annotated paired heavy and light chain sequences. To annotate these heavy and light chain sequences, select the Clinical-stage monoclonal antibodies (paired) document in the Chain association folder and click Annotation Antibody Annotator.
Select the following options from the Antibody Annotator dialog box (see sections and image below).
Select the following options:
- Reference database: Human Ig
- Selected sequences are: Both chains in associated sequences
Select the following option:
- Include pseudo genes from database
- Annotate germline gene differences
- Include numbering (IMGT only)
- Find liabilities and assets
This operation will produce a Clinical-stage antibodies (paired) Annotated & Clustered Biologics Annotator Result document.
Add assay data
Data from antibody assays can be appended to Biologics Annotator Result document. The assay data coupled with the sequence annotation, liabilities score and germline differences produced by the Antibody Annotator may aid antibody candidate selection. This can then in turn serve as an antibody registry for future analysis.
In this exercise, you will learn how to add assay data into a Biologics Annotator Result document. First you will need an excel or csv file containing your functional data. You can download one for the tutorial here. Then select the Clinical-stage monoclonal antibodies (paired) Annotated & Clustered document in the Sequence annotation folder and click Add Assay Data.
To match the columns on Name, select Name in the Matching column in the document dropdown in the Add Assay Data dialog box and click Add Assay Data to append the assay data columns (see image below).
To view the added assay data, select the Clinical-stage monoclonal antibodies (paired) Annotated & Clustered (with assay data) document in the Add assay data folder and scroll to the right end of the Sequences Table or use the Focus column button located in the Table Preferences panel.
**Note that the adding assay data does not create a new document as the assay data columns are appended to the existing Biologics Annotator Result document. For this tutorial, an identical Biologics Annotator Result was generated and the assay data was appended to the Clinical-stage monoclonal antibodies (paired) Annotated & Clustered (with assay data) document in the Add assay data folder. Learn more about adding external assay data into a Biologics Annotator Result documents here.
Multiple sequence alignment is a comparison of multiple related DNA or amino acid sequences to identify regions of similarity and dissimilarity that may be a consequence of evolutionary relationships between the sequences. Alignments can be used for many purposes including inferring the presence of evolutionary relationships between the sequences.
In this exercise, you will learn how to filter and align sequences that meet a set of conditions. To align sequences that meet the conditions of having a Score of ≥ -200 and an Elisa affinity value of ≤ 1.5, first, filter the sequences using the following filter syntax:
['Score'] >= -200 AND ['ASSAY_DATA_Biophysical_Assays:ELISA'] <= 1.5
Once the filter syntax is entered, click Filter or hit Enter. This should result in 20 heavy and light paired sequences. Subsequently, select all of the paired sequences that meet the filtering criteria and click Post-processing Align (see image below)
Select the following options in the Alignment dialog box to align the Heavy CDR3 amino acid sequences and click Run to start the analysis (see section and image below).
Region to Align
- Extract region with name: CDR3 - 20 sequences
- Filter by: Heavy Chain
Translate Nucleotide Sequence(s) Prior to Alignment
- Build tree from alignment
In the example above, although a total of 20 CDR3 regions were identified (Extract region with name), only the Heavy Chain CDR3 amino acid sequences will be aligned (Filter by). This alignment operation will produce a protein sequence alignment tree document generated with the Neighbour-Joining method.
You will now learn how to view alignment with assay data and learn how to sort the sequences on assay data. First, to view the alignment, select the 20 protein sequences alignment tree document located in the Sequence alignment folder. Then in the Sequence Viewer panel, select the following options to sort the sequences in descending Liability score and ELISA affinity value (see image below).
The alignment and sequence logos showed a relatively highly conservation of amino acid residues A1, R2, F18, D21 and Y22 of the Heavy CDR3 region (Figure 2.1).Additionally, the pairwise identity and Wu-Kabat variability graphs in the alignment show high conservation at the ends of Heavy CDR3 (Figure 2.1A).
Figure 2.1 | Conservation of amino acid residues at both ends of the Heavy CDR3 region. A) Heavy CDR3 amino acid sequence alignment sorted by descending liability score and ELISA affinity. B) Sequence logo shown as a frequency of amino acid per position. C) Sequence logo is shown as the entropy of amino acids per position.
*The colored amino acids in the alignment are in agreement with the consensus sequence while the grey amino acids are dissimilar to the consensus sequence.
**Note that the Neighbour-Joining (NJ) tree will dissolve upon sorting, to view the NJ tree, remove the sorting field. Read more about sequence alignment and sequence associated metadata here.
***Tutorial Reference - Biophysical properties of the clinical-stage antibody landscape, PNAS January 31, 2017 114 (5) 944-949; first published January 17, 2017. https://doi.org/10.1073/pnas.1616408114